Biopharma firm Suven Life Sciences today said it has been granted one patent each in 5 nations, including China and Israel, for a drug used in the treatment of neurodegenerative diseases.
Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.
In a BSE filing, the company said it has been granted "one product patent from China, one product patent from Israel, one product patent from Mexico, one product patent from Singapore and one product patent from Sri Lanka corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases."
Suven Life Sciences CEO Venkat Jasti said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."
With this development, Suven Life Sciences' total count of patents stands at 17 from China, 20 from Mexico, 21 from Singapore, 11 from Sri Lanka and 7 from Israel.
Shares of the company were trading at Rs 218.80 apiece, up 5.78 per cent, on BSE in the morning trade.
